Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP).

Rafael SegarraM Recio-BarberoM Sáenz-HerreroO MentxakaJ Cabezas-GarduñoJ I EguíluzL F Callado

Published in: The international journal of neuropsychopharmacology (2022)

To our knowledge, this is the first study assessing the use of palmitate paliperidone long-acting formulations versus oral risperidone or paliperidone in FEP. Treatment with PPLAI formulations seems to be an effective therapeutic choice at earlier stages of the disease.

Keyphrases

randomized controlled trial
bipolar disorder
healthcare
quality improvement
combination therapy
decision making